Avenue Therapeutics Reports Q2 2026 Financial Results with $690,000 Net Loss

Avenue Therapeutics, Inc. reported its financial results for the second quarter of 2026, revealing a net loss of $690,000, compared to a net income of $335,000 in the same period of 2025. The company did not generate any revenue during the quarter, a significant decline from the $1.4 million reported in the prior year, which was attributed to the termination of a license agreement with AnnJi Pharmaceutical Co. The total operating expenses for the quarter were $707,000, down 36% from $1.1 million in the previous year, primarily due to reduced general and administrative costs.

For the first half of 2026, Avenue Therapeutics recorded a net loss of $1.4 million, slightly improved from a loss of $1.5 million in the same period of 2025. Operating expenses for the six months ended June 30, 2026, were $1.4 million, a decrease of 53% compared to $3.0 million in the prior year. The reduction in expenses was driven by lower general and administrative costs, which fell from $2.4 million to $974,000, reflecting a decrease in legal and personnel-related expenses.

The company’s cash and cash equivalents stood at $1.9 million as of June 30, 2026, down from $2.9 million at the end of 2025. Avenue Therapeutics has indicated that it will require additional funding to support its ongoing operations and product development, particularly for its lead candidates, ATX-04 and IV tramadol. The company is exploring various financing options, including equity or debt offerings, but has expressed uncertainty regarding the availability of such funding on favorable terms.

In terms of strategic developments, Avenue Therapeutics entered into a license agreement with Duke University in February 2026 for ATX-04, a treatment for lysosomal storage diseases. The agreement includes upfront payments and milestone obligations, as well as royalties on future sales. The company is also preparing for a pivotal study for ATX-04 and is in discussions with the FDA regarding the study design for IV tramadol, which is intended to assess the risk of respiratory depression.

Looking ahead, Avenue Therapeutics anticipates continued operating losses as it advances its product candidates through clinical development. The company has highlighted the need for substantial additional funding to support its business plan and has acknowledged the challenges posed by its current status as a smaller reporting company, which may limit its access to capital markets. The management remains focused on securing the necessary resources to continue its operations and achieve its strategic objectives.